TP53 and chronic kidney disease: Further exploration of cell signals (FOXO1, PGC-1α, SIRT1, p53, SMADs, MALAT1) altered in CKD and modulated by ncRNAs and NAD metabolites may offer insight into novel therapeutic approaches.